The decades-long battle against smoking may have a surprising fresh ally: psilocybin, the active compound in magic mushrooms. A new study published Tuesday in JAMA Network Open reveals that a single dose of psilocybin, combined with cognitive behavioral therapy, dramatically increased the odds of successful smoking cessation compared to traditional nicotine replacement therapy.
Researchers at Johns Hopkins University found that participants who received psilocybin were more than six times more likely to remain abstinent from cigarettes after six months than those who used nicotine patches. This groundbreaking research adds to a growing body of evidence suggesting that psychedelic-assisted therapies could revolutionize the treatment of addiction, offering hope to the millions worldwide struggling to quit smoking – a habit responsible for nearly half a million deaths annually in the United States, according to the Centers for Disease Control and Prevention. CDC Swift Facts
The study involved 82 current smokers who were randomly assigned to receive either a single dose of psilocybin or continue with nicotine patches, all although undergoing 13 weeks of cognitive behavioral therapy. “I was surprised by the sheer magnitude of the effect,” said Matthew Johnson, the study’s author and a professor of psychiatry at Johns Hopkins University. Participants who received psilocybin ingested a relatively high dose of the substance in a carefully monitored setting, lying with eye shades on while listening to soft music, allowing for a “self-directed” experience.
While the study didn’t include a traditional placebo group – a common challenge in psychedelic research due to the unmistakable effects of the drug – researchers opted for a design that acknowledged participants were receiving psilocybin. This approach, Johnson explained, was necessary given the inherent difficulty of blinding participants to the psychedelic experience. At the six-month mark, 17 of the 41 participants in the psilocybin group had remained smoke-free, compared to just four of the 41 in the nicotine patch group.
A Novel Approach to Addiction Treatment
Experts are cautiously optimistic about the findings. Megan Piper, who directs the UW Center for Tobacco Research Intervention and was not involved in the study, called the results “exciting,” noting that it’s been two decades since a truly new medication for smoking cessation has been introduced. “We necessitate something novel, and this is definitely a novel approach,” she said. Currently, seven medications are available to help people quit smoking, including nicotine replacement products like gums, lozenges, and patches, as well as varenicline and bupropion. CDC – Medications to Help You Quit A third medication could receive approval later this year.
However, even with medication and counseling, long-term success rates hover between 20% and 30%, leaving a significant portion of smokers still struggling with addiction. “That still means 70% of people are returning to smoking. So how do we help those folks?” Piper asked.
Beyond Smoking: Psychedelics and Addiction
The potential of psilocybin extends beyond smoking cessation. Research suggests promise in treating other addictions, including alcohol dependence and opioid use disorder. Interest in ibogaine, a naturally occurring psychoactive compound, is also growing in the context of opioid addiction treatment. However, investment in psychedelic research has largely focused on mental health conditions like depression, anxiety, and post-traumatic stress disorder, according to Dr. Brian Barnett, an addiction psychiatrist at the Cleveland Clinic Lerner College of Medicine.
Barnett emphasized that this research is “cutting-edge work” given the significant public health burden of smoking. Unlike traditional smoking cessation medications that target nicotine receptors, psilocybin offers a fundamentally different approach. “It’s a remarkably different treatment approach from just trying to replace or sort of mimic the drug that’s being misused,” he explained. He also highlighted the importance of the intensive therapeutic support provided alongside the psilocybin treatment, suggesting that the combination is key to its success. “It’s not the drug by itself here,” he said. “It’s really harnessing the neuroplastic and learning effects that happen after the [drug] exposure.”
This latest study builds on earlier research conducted by Johnson over a decade ago, which initially demonstrated the potential of psilocybin for smoking cessation. Those earlier findings led to funding from the National Institutes of Health for a larger, ongoing trial that will include a placebo arm.
Researchers are currently analyzing brain imaging data from the study, hoping to gain further insights into the mechanisms behind psilocybin’s effectiveness. Johnson noted that psilocybin appears to alter brain communication patterns, and conversations with past study participants suggest it can facilitate a shift in perspective and a renewed sense of agency. “Rather than falling into the same stories, these same patterns, things are shaken up and they can step outside of that and try something different,” he said.
While further research is needed, these findings represent a significant step forward in the search for more effective treatments for smoking addiction. The ongoing trials, and the continued exploration of psychedelics’ potential, could pave the way for a new era in addiction medicine.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential of psilocybin-assisted therapy? Share your comments below, and please share this article with anyone who might find it helpful.
